# Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia

> **NCT00842894** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 3421 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin detemir
- **DRUG:** biphasic insulin aspart 30

## Key facts

- **NCT ID:** NCT00842894
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 3421 (ACTUAL)
- **Last updated:** 2014-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00842894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00842894, "Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00842894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*